BioInvent International AB (publ) (BINV.ST)
SEK 39.75
(2.45%)
SEK 39.75
(2.45%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -369.94 Million SEK | -627.75% |
| 2022 | -50.92 Million SEK | 81.71% |
| 2021 | -278.35 Million SEK | -268.8% |
| 2020 | -75.47 Million SEK | 45.25% |
| 2019 | -137.84 Million SEK | -11.86% |
| 2018 | -123.23 Million SEK | -22.46% |
| 2017 | -100.63 Million SEK | -60.09% |
| 2016 | -62.85 Million SEK | 33.81% |
| 2015 | -94.97 Million SEK | -72.91% |
| 2014 | -54.92 Million SEK | -186.43% |
| 2013 | -19.17 Million SEK | 89.97% |
| 2012 | -191.09 Million SEK | -166.67% |
| 2011 | -71.66 Million SEK | 43.95% |
| 2010 | -127.84 Million SEK | 28.78% |
| 2009 | -179.5 Million SEK | -2831.73% |
| 2008 | 6.57 Million SEK | -71.98% |
| 2007 | 23.44 Million SEK | 120.99% |
| 2006 | -111.73 Million SEK | 21.5% |
| 2005 | -142.33 Million SEK | -45.09% |
| 2004 | -98.1 Million SEK | -197.38% |
| 2003 | 100.74 Million SEK | 61.41% |
| 2002 | 62.41 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -107.52 Million SEK | 27.83% |
| 2024 Q1 | -89.74 Million SEK | 19.45% |
| 2024 Q2 | -148.46 Million SEK | -65.43% |
| 2023 Q3 | -81.48 Million SEK | 15.78% |
| 2023 Q2 | -96.75 Million SEK | -19.53% |
| 2023 Q1 | -80.94 Million SEK | -2.12% |
| 2023 FY | -370.57 Million SEK | -627.75% |
| 2023 Q4 | -111.41 Million SEK | -36.74% |
| 2022 Q2 | 165.54 Million SEK | 342.42% |
| 2022 FY | -50.92 Million SEK | 81.71% |
| 2022 Q4 | -79.26 Million SEK | -14.62% |
| 2022 Q3 | -69.15 Million SEK | -141.77% |
| 2022 Q1 | -68.28 Million SEK | 13.39% |
| 2021 Q4 | -78.84 Million SEK | -26.3% |
| 2021 Q2 | -57.1 Million SEK | 28.58% |
| 2021 FY | -278.35 Million SEK | -268.8% |
| 2021 Q3 | -62.43 Million SEK | -9.32% |
| 2021 Q1 | -79.96 Million SEK | -371.92% |
| 2020 Q1 | -32.97 Million SEK | 18.51% |
| 2020 Q2 | -39.09 Million SEK | -18.58% |
| 2020 Q4 | 29.4 Million SEK | 189.62% |
| 2020 Q3 | -32.81 Million SEK | 16.07% |
| 2020 FY | -75.47 Million SEK | 45.25% |
| 2019 Q1 | -27.71 Million SEK | 15.12% |
| 2019 FY | -137.84 Million SEK | -11.86% |
| 2019 Q3 | -37 Million SEK | -13.26% |
| 2019 Q4 | -40.45 Million SEK | -9.34% |
| 2019 Q2 | -32.67 Million SEK | -17.87% |
| 2018 Q1 | -24.94 Million SEK | 25.12% |
| 2018 Q2 | -43.26 Million SEK | -73.43% |
| 2018 FY | -123.23 Million SEK | -22.46% |
| 2018 Q3 | -22.36 Million SEK | 48.31% |
| 2018 Q4 | -32.65 Million SEK | -46.01% |
| 2017 Q4 | -33.31 Million SEK | -55.3% |
| 2017 Q3 | -21.45 Million SEK | 8.79% |
| 2017 Q1 | -22.34 Million SEK | -204.89% |
| 2017 FY | -100.63 Million SEK | -60.09% |
| 2017 Q2 | -23.52 Million SEK | -5.28% |
| 2016 FY | -62.85 Million SEK | 33.81% |
| 2016 Q3 | -28.56 Million SEK | -5.2% |
| 2016 Q2 | -27.14 Million SEK | -15352.25% |
| 2016 Q1 | 178 Thousand SEK | 100.7% |
| 2016 Q4 | -7.32 Million SEK | 74.34% |
| 2015 Q4 | -25.4 Million SEK | -12.73% |
| 2015 FY | -94.97 Million SEK | -72.91% |
| 2015 Q3 | -22.53 Million SEK | 10.71% |
| 2015 Q2 | -25.23 Million SEK | -15.76% |
| 2015 Q1 | -21.8 Million SEK | 24.02% |
| 2014 Q2 | 3.42 Million SEK | 117.93% |
| 2014 Q4 | -28.69 Million SEK | -171.47% |
| 2014 Q1 | -19.08 Million SEK | -195.89% |
| 2014 FY | -54.92 Million SEK | -186.43% |
| 2014 Q3 | -10.56 Million SEK | -408.85% |
| 2013 Q4 | 19.9 Million SEK | 234.21% |
| 2013 Q2 | -10.23 Million SEK | 26.96% |
| 2013 FY | -19.17 Million SEK | 89.97% |
| 2013 Q1 | -14.01 Million SEK | 37.78% |
| 2013 Q3 | -14.83 Million SEK | -44.89% |
| 2012 Q1 | -37.56 Million SEK | 38.51% |
| 2012 Q3 | -37.75 Million SEK | 59.51% |
| 2012 Q4 | -22.52 Million SEK | 40.35% |
| 2012 FY | -191.09 Million SEK | -166.67% |
| 2012 Q2 | -93.25 Million SEK | -148.26% |
| 2011 Q4 | -61.09 Million SEK | -63.38% |
| 2011 Q3 | -37.39 Million SEK | -16.02% |
| 2011 Q2 | -32.22 Million SEK | -154.58% |
| 2011 Q1 | 59.05 Million SEK | 238.22% |
| 2011 FY | -71.66 Million SEK | 43.95% |
| 2010 FY | -127.84 Million SEK | 28.78% |
| 2010 Q4 | -42.72 Million SEK | -72.44% |
| 2010 Q3 | -24.77 Million SEK | -8.04% |
| 2010 Q2 | -22.93 Million SEK | 38.71% |
| 2010 Q1 | -37.41 Million SEK | 18.73% |
| 2009 Q3 | -42.8 Million SEK | 21.19% |
| 2009 Q2 | -54.31 Million SEK | -49.47% |
| 2009 FY | -179.5 Million SEK | -2831.73% |
| 2009 Q4 | -46.03 Million SEK | -7.55% |
| 2009 Q1 | -36.34 Million SEK | 0.0% |
| 2008 FY | 6.57 Million SEK | -71.98% |
| 2007 FY | 23.44 Million SEK | 120.99% |
| 2006 FY | -111.73 Million SEK | 21.5% |
| 2005 FY | -142.33 Million SEK | -45.09% |
| 2004 FY | -98.1 Million SEK | -197.38% |
| 2003 FY | 100.74 Million SEK | 61.41% |
| 2002 FY | 62.41 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | -48.581% |
| Ziccum AB (publ) | -21.56 Million SEK | -1615.872% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -2155.606% |
| BioArctic AB (publ) | 252.64 Million SEK | 246.43% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -43680.118% |
| Mendus AB (publ) | -100.65 Million SEK | -267.553% |
| Genovis AB (publ.) | 54.22 Million SEK | 782.248% |
| Intervacc AB (publ) | -93.57 Million SEK | -295.326% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -2284.876% |
| Active Biotech AB (publ) | -46.48 Million SEK | -695.848% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 2154.206% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -567.56% |
| Aptahem AB (publ) | -10.1 Million SEK | -3561.067% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | -15.065% |
| Kancera AB (publ) | -65.04 Million SEK | -468.774% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | -174.811% |
| Fluicell AB (publ) | -26.87 Million SEK | -1276.324% |
| Saniona AB (publ) | -81.06 Million SEK | -356.352% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -2890.397% |
| Biovica International AB (publ) | -126.07 Million SEK | -193.435% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -770.349% |
| AcouSort AB (publ) | -17.48 Million SEK | -2015.526% |
| Xintela AB (publ) | -57.23 Million SEK | -546.322% |
| Abliva AB (publ) | -96.54 Million SEK | -283.169% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | -13.898% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -10454.693% |
| OncoZenge AB (publ) | -15.9 Million SEK | -2226.387% |
| Amniotics AB (publ) | -29.07 Million SEK | -1172.459% |
| 2cureX AB (publ) | -36.36 Million SEK | -917.358% |
| CombiGene AB (publ) | -36.3 Million SEK | -918.979% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -2426.926% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 3.76% |
| Camurus AB (publ) | 532.35 Million SEK | 169.492% |
| Corline Biomedical AB | -1.78 Million SEK | -20590.268% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | -104.654% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -787.513% |
| I-Tech AB | 24.43 Million SEK | 1613.984% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 53.083% |
| Cyxone AB (publ) | -21.66 Million SEK | -1607.871% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -249.117% |
| Biosergen AB | -27.26 Million SEK | -1256.838% |
| Cantargia AB (publ) | -290.01 Million SEK | -27.559% |
| NextCell Pharma AB | -43.17 Million SEK | -756.9% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | -104.654% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -2063.875% |
| Nanologica AB (publ) | -69.96 Million SEK | -428.768% |
| SynAct Pharma AB | -224.49 Million SEK | -64.788% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -737.428% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -1444.368% |
| LIDDS AB (publ) | -40.67 Million SEK | -809.529% |
| Lipum AB (publ) | -37.25 Million SEK | -893.026% |
| Alzinova AB (publ) | -16.52 Million SEK | -2139.087% |
| Oncopeptides AB (publ) | -253.44 Million SEK | -45.964% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -5686.448% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | -221.485% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -1736.943% |
| Simris Alg AB (publ) | -36.63 Million SEK | -909.805% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | -152.405% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | -19.172% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -233.539% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -3098.53% |